Original blog due diligence on 7/10 http://www.precisiontrade365.com/new-biotech-mid-cap-pick-for-elite-membership-12-months-7-10-18/ update charts:
AGN invalidates Undervalued thesis, it faces many risks on recent Senate probes, FDA refusal letter for their Vraylar and Restasis patent. AGN -15% since pulished
CYRX +40% since published on $5 -$7; no more updates on this. Congratulations on profits.
Elite small cap biotech pick hit target. Trim and trail. Blog article on 3/07/17 http://www.precisiontrade365.com/new-small-cap-biotech-idea-3-7-17/ Chart on March 7, 2017 pick for elite membership. after chart as of April 4/25/17
Long ago, Ben Graham taught me that price is what you pay, value is what you get. Whether we are talking about socks or stocks, I like buying quality merchandise when it is marked down. -Warren Buffett
You need to divorce your mind from the crowd. The herd mentality causes all these IQ's to become paralyzed. I don't think investors are now acting more intelligently, despite the intelligence. Smart doesn't always equal rational. To be a successful investor you must divorce yourself from the fears and greed of the people around you, [...]